Tykerb was developed as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine (Xeloda TM).
Tykerb successfully underwent a trial involving 45 patients revealing significant tumor regression after just six weeks of use. The number of cancer-causing stem cells swooped down from 10.6 percent to 4.7 percent.
The study once more proved that it’s more effective to target stem cells and “go by” unpleasant side effects associated with conventional chemotherapy treatment.
The results of the study were revealed at the sixth European Breast Cancer Conference in Berlin.
The behavior of the Russian inspector satellite, which was launched in the autumn of 2017, puzzles military officials in the United States
Ukrainian bloggers draw a parallel between the events in East Timor and the Crimea. Any comparison has a right to exist, but a detailed analysis of the situation does not give a promising forecast to Ukraine
Vladimir Putin is planning to attend the wedding ceremony of Austria's Foreign Minister Karin Kneissl on the way to Berlin